Longterm Follow-up of Patients in CSP Number 298 , Treatment of Patients with 'Acquired Immune Deficiency Syndrome (AIDS) and AIDS related Complex'.
Abstract
To evaluate the benefits of early (E) vs. Later (L) ZDV therapy, we enrolled 338 symptomatic HIV+ patients with CD4 counts of 200-500/cmm into a randomized, double-blind trial. Patients were assigned to initial ZDV 1,500 mg/day (E: 168 pts) or initial placebo (L. 170 The latter were switched to ZDV after progression to AIDS or to a court <200/cmm. All pts were offered ZDV 500 mg/day following completion of blinded follow-up. Blinded and final follow-up were completed in January 1991 and 1994, respectively. Median follow-up was 52 months. Progressions to AIDS occurred in 67 and 84 pts in the E and L therapy groups, respectively (rel. risk, 0.73; 95% CI, 0.52- l.01; p = 0.054). Death occurred in 74 and 73 pts in the E and L therapy groups, respectively (rel. risk, 0.99; 95% CI, 0.72-1.37; ns). We conclude that early compared with later ZDV provides marginal protection against progression to AIDS but no survival benefit.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 1994
- Accession Number
- ADA288508
Entities
People
- John D. Hamilton
- Michael S. Simberkoff
- Pamela M. Hartigan
Organizations
- Veterans Administration Medical Center